First Spanish HIV vaccine proves safe in phase I trialsBMJ 2011; 343 doi: http://dx.doi.org/10.1136/bmj.d6327 (Published 03 October 2011) Cite this as: BMJ 2011;343:d6327
- Ainhoa Iriberri
The first Spanish prototype of a vaccine against HIV has proved to be safe in a small phase I trial conducted in healthy volunteers in Madrid and Barcelona. Although the first phase is intended only to test the safety of the compound, which is known as MVA-B, the study has also shown a good immunological response among the participants.
The vaccine uses a poxvirus (modified vaccinia Ankara (MVA)) as a vector to insert the combination of four HIV genes.
Thirty healthy volunteers participated in the new phase I clinical trial, named RISVAC02 (Vaccine doi:10.1016/j.vaccine.2011.08.098. Twenty four received MVA-B (three injections in weeks 0, 4, and 16 of the trial) and the other six a placebo. …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial